PDCL3

Across TCGA pan-cancer cohorts, PDCL3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PDCL3 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PDCL3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PDCL3 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, LUAD, and LSCC are the cancer types where PDCL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	III,IV	0.437	0.823	<.001	56	view →
LUAD	OS	Quartile	II,III,IV	0.267	1.000	.007	17	view →
LSCC	DFS	Median	III,IV	0.374	0.864	.013	7	view →
PDAC	DFS	Tertile	All	0.931	0.692	.028	3	view →
GBM	DFS	Median	All	0.295	0.443	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PDCL3–CCRCC (OS)

Open the CCRCC breakdown →